Solventum Corp (SOLV)
Solventum Corp (SOLV) from its SEC filings: 2025 revenue $8.3 billion (+1% vs the year before), net margin 19%, free cash flow -$10.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Surgical & Medical Instruments & Apparatus |
| Revenue (2025) | $8.3 billion |
| Revenue growth | +1% |
| Net income | $1.6 billion |
| Net margin | 18.7% |
| Free cash flow | -$10.0 million |
| Diluted EPS | $8.88 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +2% |
| Cash | $403.0 million |
| Long-term debt | $4.6 billion |
| Share count, 1 year | -2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.